Your browser doesn't support javascript.
loading
Proteomic-based stratification of intermediate-risk prostate cancer patients.
Zhong, Qing; Sun, Rui; Aref, Adel T; Noor, Zainab; Anees, Asim; Zhu, Yi; Lucas, Natasha; Poulos, Rebecca C; Lyu, Mengge; Zhu, Tiansheng; Chen, Guo-Bo; Wang, Yingrui; Ding, Xuan; Rutishauser, Dorothea; Rupp, Niels J; Rueschoff, Jan H; Poyet, Cédric; Hermanns, Thomas; Fankhauser, Christian; Rodríguez Martínez, María; Shao, Wenguang; Buljan, Marija; Neumann, Janis Frederick; Beyer, Andreas; Hains, Peter G; Reddel, Roger R; Robinson, Phillip J; Aebersold, Ruedi; Guo, Tiannan; Wild, Peter J.
Afiliación
  • Zhong Q; https://ror.org/01bsaey45 ProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.
  • Sun R; https://ror.org/05hfa4n20 iMarker Lab, Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, China.
  • Aref AT; Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou, China.
  • Noor Z; https://ror.org/01bsaey45 ProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.
  • Anees A; https://ror.org/01bsaey45 ProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.
  • Zhu Y; https://ror.org/01bsaey45 ProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.
  • Lucas N; https://ror.org/05hfa4n20 iMarker Lab, Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, China.
  • Poulos RC; Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou, China.
  • Lyu M; https://ror.org/01bsaey45 ProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.
  • Zhu T; https://ror.org/01bsaey45 ProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.
  • Chen GB; https://ror.org/05hfa4n20 iMarker Lab, Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, China.
  • Wang Y; Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou, China.
  • Ding X; https://ror.org/05hfa4n20 iMarker Lab, Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, China.
  • Rutishauser D; Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou, China.
  • Rupp NJ; Urology & Nephrology Center, Department of Urology, Clinical Research Institute, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.
  • Rueschoff JH; https://ror.org/05hfa4n20 iMarker Lab, Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, China.
  • Poyet C; Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou, China.
  • Hermanns T; https://ror.org/05hfa4n20 iMarker Lab, Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, China.
  • Fankhauser C; Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou, China.
  • Rodríguez Martínez M; Department of Pathology and Molecular Pathology, University Hospital Zürich, Zürich, Switzerland.
  • Shao W; Department of Pathology and Molecular Pathology, University Hospital Zürich, Zürich, Switzerland.
  • Buljan M; Department of Pathology and Molecular Pathology, University Hospital Zürich, Zürich, Switzerland.
  • Neumann JF; Department of Urology, University Hospital Zürich, Zürich, Switzerland.
  • Beyer A; Department of Urology, University Hospital Zürich, Zürich, Switzerland.
  • Hains PG; Department of Urology, University Hospital Zürich, Zürich, Switzerland.
  • Reddel RR; Department of Urology, Cantonal Hospital Lucerne, Lucerne, Switzerland.
  • Robinson PJ; IBM Zürich Research Laboratory, Zürich, Switzerland.
  • Aebersold R; State Key Laboratory of Microbial Metabolism, Joint International Research Laboratory of Metabolic and Developmental Sciences, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
  • Guo T; Empa - Swiss Federal Laboratories for Materials Science and Technology, St. Gallen, Switzerland.
  • Wild PJ; Swiss Institute of Bioinformatics, Lausanne, Switzerland.
Life Sci Alliance ; 7(2)2024 02.
Article en En | MEDLINE | ID: mdl-38052461
ABSTRACT
Gleason grading is an important prognostic indicator for prostate adenocarcinoma and is crucial for patient treatment decisions. However, intermediate-risk patients diagnosed in the Gleason grade group (GG) 2 and GG3 can harbour either aggressive or non-aggressive disease, resulting in under- or overtreatment of a significant number of patients. Here, we performed proteomic, differential expression, machine learning, and survival analyses for 1,348 matched tumour and benign sample runs from 278 patients. Three proteins (F5, TMEM126B, and EARS2) were identified as candidate biomarkers in patients with biochemical recurrence. Multivariate Cox regression yielded 18 proteins, from which a risk score was constructed to dichotomize prostate cancer patients into low- and high-risk groups. This 18-protein signature is prognostic for the risk of biochemical recurrence and completely independent of the intermediate GG. Our results suggest that markers generated by computational proteomic profiling have the potential for clinical applications including integration into prostate cancer management.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Proteómica Idioma: En Revista: Life Sci Alliance Año: 2024 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Proteómica Idioma: En Revista: Life Sci Alliance Año: 2024 Tipo del documento: Article